• China’s NMPA granted conditional marketing clearance for TY-9591, a next-generation EGFR-TKI, for first-line EGFR-mutant NSCLC with CNS metastases.
• Authorization covers adult patients with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12303233), on August 27, 2026, and is solely responsible for the information contained therein.